Kite Pharma (KITE) Tops Q4 EPS by 44c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Kite Pharma (KITE) Tops Q4 EPS by 44c

Kite Reports Fourth Quarter and Full Year 2016 Financial Results

February 28, 2017 8:00 AM EST

Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 Potential U.S. Approval and Launch of Axicabtagene Ciloleucel Expected in 2017 Conference Call to Be Held Today at 9:00 AM Eastern Time

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today provided a corporate update and reported fourth quarter and full-year 2016... More